<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04582955</url>
  </required_header>
  <id_info>
    <org_study_id>CSIIT-C03</org_study_id>
    <nct_id>NCT04582955</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy</brief_title>
  <official_title>Chidamide Combined With Neoadjuvant Chemotherapy in Early Triple-negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective to evaluate the efficacy and safety of neoadjuvant therapy with Chidamide combined&#xD;
      with chemotherapy for stage II - III triple-negative breast cancer，and to compare the&#xD;
      efficacy and safety of chemotherapy with Chidamide and chemotherapy alone in the neoadjuvant&#xD;
      treatment of stage II - III triple-negative breast cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 30, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy Outcome: pathologic complete response（pCR） rate（ypT0/is ypN0）</measure>
    <time_frame>1years</time_frame>
    <description>pCR defined as no invasive tumour residuals in breast and no invasive and no non-invasive tumour residuals in axillary lymph nodes (ypT0/is ypN0) after neoadjuvant therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) by RECIST v1.1</measure>
    <time_frame>12 months</time_frame>
    <description>Objective Response Rate (ORR) by RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pCR by other definitions</measure>
    <time_frame>12 months</time_frame>
    <description>response by other pCR definitions（ypT0 ypN0; ypT0 ypN0/+;ypT0/is ypN0/+; ypT[any] ypN0）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast conserving surgery rate</measure>
    <time_frame>12 months</time_frame>
    <description>Breast conserving surgery rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>60 months</time_frame>
    <description>Event-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>72 months</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of Adverse Events (AEs)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Triple-negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chidamide, orally,20mg at day 0,4,7,11,21,every 3 weeks; in combination with Docetaxel 75mg/m2,intravenous infusion，at day1 every 3 weeks，and Epirubicin 75mg/m2, intravenous infusion，at day1 every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chidamide in combination with chemotherapy</intervention_name>
    <description>Chidamide, orally,20mg at day 0,4,7,11,21,every 3 weeks; in combination with Docetaxel 75mg/m2,intravenous infusion，at day1 every 3 weeks，and Epirubicin 75mg/m2, intravenous infusion，at day1 every 3 weeks</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Other Name: For Chidamide: HBI-8000, CS055</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 and ≤ 70, postmenopausal / premenopausal women;&#xD;
&#xD;
          2. Patients with unilateral or bilateral primary invasive triple-negative (ER expression&#xD;
             &lt; 1%, PR &lt; 1%, and HER2 negative *) confirmed by histology or cytology;&#xD;
&#xD;
          3. non-metastatic invasive TNBC（stage II-III）with at least one axillary lymph node&#xD;
             involvement (T1cN1-2M0 or T2-3N1-2M0);&#xD;
&#xD;
          4. previously untreated for breast cancer;&#xD;
&#xD;
          5. There was at least one measurable primary lesion (according to RECIST v1.1);&#xD;
&#xD;
          6. ECoG score 0-1;&#xD;
&#xD;
          7. Adequate organ and marrow function as defined below:&#xD;
&#xD;
             absolute value of neutrophils ≥ 1.5 × 109 / L, platelets ≥ 100 × 109 / L, hemoglobin≥&#xD;
             90 g / L;&#xD;
&#xD;
          8. Volunteer to participate in this clinical trial and sign written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. No measurable lesions, such as pleural or pericardial effusion, ascites, etc;&#xD;
&#xD;
          2. Major surgical procedures or significant trauma were performed within 4 weeks before&#xD;
             enrollment, or patients were expected to receive major surgical treatment (not related&#xD;
             to breast cancer);&#xD;
&#xD;
          3. Previously treated with chemotherapy or HDAC inhibitors (including romidepsin,&#xD;
             vorinostat, belinostat, and panobinostat，etc);&#xD;
&#xD;
          4. Have allergic history to the components of this regimen;&#xD;
&#xD;
          5. Treated with radiotherapy within 4 weeks before admission;&#xD;
&#xD;
          6. Have a history of immunodeficiency, including HIV positive, or other acquired or&#xD;
             congenital immunodeficiency diseases, or have a history of organ transplantation;&#xD;
&#xD;
          7. Uncontrolled cardiovascular diseases, history of clinically significant QT interval&#xD;
             prolongation, or QTc interval &gt; 450 ms at screening;&#xD;
&#xD;
          8. Abnormal liver function [total bilirubin &gt; 1.5 times of the upper limit of normal&#xD;
             value; ALT / AST &gt; 2.5 times of upper limit of normal value for patients without liver&#xD;
             metastasis ; ALT / AST &gt; 5 times of upper limit of normal value for patients with&#xD;
             liver metastasis ], abnormal renal function (serum creatinine &gt; 1.5 times of upper&#xD;
             limit of normal value);&#xD;
&#xD;
          9. Pregnant, lactating or fertile women with a positive baseline pregnancy test; or&#xD;
             subjects of childbearing age who are not willing to take effective contraceptive&#xD;
             measures during the study period and at least 8 weeks after the last administration;&#xD;
&#xD;
         10. According to the judgment of the investigator, there are some concomitant diseases&#xD;
             (such as severe hypertension, diabetes, thyroid disease, active infection, etc.) that&#xD;
             seriously endanger the safety of patients or affect patients to complete the study;&#xD;
&#xD;
         11. A clear history of epilepsy or dementia, including neurological disorders;&#xD;
&#xD;
         12. The investigator determined not suitable to participate in this study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jin Zhang, professor</last_name>
    <phone>0086-22-2340 123</phone>
    <phone_ext>2121</phone_ext>
    <email>zhangjin@tjmuch.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Zhang, M.D,Ph.D</last_name>
      <phone>0086-22-2340 123</phone>
      <phone_ext>2121</phone_ext>
      <email>zhangjin@tjmuch.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 28, 2020</study_first_submitted>
  <study_first_submitted_qc>October 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2020</study_first_posted>
  <last_update_submitted>December 3, 2020</last_update_submitted>
  <last_update_submitted_qc>December 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neoadjuvant</keyword>
  <keyword>Chidamide</keyword>
  <keyword>triple-negative breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

